Spots Global Cancer Trial Database for mycosis fungoides
Every month we try and update this database with for mycosis fungoides cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809 | Chronic Lymphoi... Lymphoid Malign... Non-Hodgkin's L... Follicular Lymp... Mantle Cell Lym... Peripheral T-ce... | ABT-263 | 18 Years - 99 Years | AbbVie | |
| Histopathological Changes in Mycosis Fungoides | NCT05904522 | Mycosis Fungoid... | biopsy | 18 Years - 100 Years | Bezmialem Vakif University | |
| Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | NCT04904146 | Mycosis Fungoid... Sezary Syndrome | Blood tests and... | 18 Years - 100 Years | Lund University Hospital | |
| The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients | NCT06421571 | Mycosis Fungoid... | 18 Years - | National and Kapodistrian University of Athens | ||
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | NCT05357794 | Mycosis Fungoid... | Brentuximab ved... | 18 Years - | M.D. Anderson Cancer Center | |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | NCT00047060 | Mycosis Fungoid... Sezary Syndrome | A matched perip... cyclosporine fludarabine Campath | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | NCT00071071 | Cutaneous T-Cel... | HuMax-CD4 HuMax-CD4 | 18 Years - | Genmab | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides | NCT05526638 | Mycosis Fungoid... | ultraviolet pho... | 18 Years - | Cairo University | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | NCT03587844 | Mycosis Fungoid... Lymphomatoid Pa... Sezary Syndrome | brentuximab ved... brentuximab ved... brentuximab ved... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | NCT04256018 | Sezary Syndrome Mycosis Fungoid... | Mogamulizumab LD TSEBT | 18 Years - | Stanford University | |
| Ritlecitinib in CTCL | NCT05879458 | CTCL Mycosis Fungoid... Sezary Syndrome | Ritlecitinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | NCT02943642 | Mycosis Fungoid... | A-dmDT390-bisFv... Vorinostat | 18 Years - | Angimmune LLC | |
| TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | NCT02822586 | Mycosis Fungoid... Sézary Syndrome | TSEB Therapy Brentuximab ved... | 18 Years - | Virginia Commonwealth University | |
| Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas | NCT02323659 | Lymphoma, T-Cel... Mycosis Fungoid... | Methotrexate Interferon Alfa... | 18 Years - | Polish Lymphoma Research Group | |
| Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | NCT00157274 | Mycosis Fungoid... Sezary Syndrome | alemtuzumab | 18 Years - 75 Years | Latin American Cooperative Onco-Haematology Group - Peru | |
| Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | NCT00168064 | Mycosis Fungoid... | mechlorethamine... | - | Yaupon Therapeutics | |
| A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | NCT05296304 | Cutaneous T-cel... | Bexarotene Total Skin Elec... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | NCT05855460 | Mycosis Fungoid... | Skin biopsy | 18 Years - | Cairo University | |
| Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) | NCT00490776 | Cutaneous T-Cel... | Panobinostat | 18 Years - | Novartis | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | NCT04955340 | Cutaneous T Cel... Mycosis Fungoid... Sezary Syndrome | [14C]-resminost... | 35 Years - 55 Years | 4SC AG | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides | NCT00496743 | Mycosis Fungoid... | Low-dose total ... | 18 Years - | Bispebjerg Hospital | |
| Ritlecitinib in CTCL | NCT05879458 | CTCL Mycosis Fungoid... Sezary Syndrome | Ritlecitinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | NCT01445340 | Mycosis Fungoid... Cutaneous T-Cel... Neoplasms | Romidepsin (FR9... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | NCT00038376 | Lymphoma, T-Cel... Mycosis Fungoid... Hematologic Neo... | Isotretinoin (A... Interferon Alph... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) | NCT01578499 | Primary Cutaneo... Mycosis Fungoid... Cutaneous T-Cel... | Brentuximab Ved... Methotrexate Bexarotene | 18 Years - | Takeda | |
| Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | NCT01556828 | Cutaneous Lymph... Other Skin Diso... Mycosis Fungoid... Cutaneous T-cel... | 18 Years - | Stanford University | ||
| Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | NCT00226993 | Mycosis Fungoid... | CPG 7909 | 18 Years - | Stanford University | |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | NCT05357794 | Mycosis Fungoid... | Brentuximab ved... | 18 Years - | M.D. Anderson Cancer Center | |
| Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) | NCT06235281 | Mycosis Fungoid... | Mogamulizumab-K... Phototherapy | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides | NCT03288818 | Mycosis Fungoid... | Mechlorethamine... Total Skin Elec... | 18 Years - | Thomas Jefferson University | |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma | NCT02341209 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Doxycycline mon... | 18 Years - | Rochester General Hospital | |
| Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides | NCT03454945 | Lymphoma | Vibramycin Phototherapy | 18 Years - | Cairo University | |
| Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | NCT03398161 | Localized Skin ... Mycosis Fungoid... | Quality-of-Life... Questionnaire A... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides | NCT05526638 | Mycosis Fungoid... | ultraviolet pho... | 18 Years - | Cairo University | |
| Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) | NCT06235281 | Mycosis Fungoid... | Mogamulizumab-K... Phototherapy | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT01590732 | Mycosis Fungoid... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Hepat... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Hepa... Refractory Peri... | Carboplatin Etoposide Ifosfamide Romidepsin | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Mechlorethamine Induced Contact Dermatitis Avoidance Study | NCT03380026 | Cutaneous T-cel... Cutaneous T-cel... Mycosis Fungoid... Folliculotropic... Granulomatous S... Syringotropic M... Mycosis Fungoid... Transformed Myc... | Triamcinolone Valchlor 0.016 ... | 18 Years - | Rochester Skin Lymphoma Medical Group, PLLC | |
| In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) | NCT00177190 | Cutaneous T-cel... Sezary Syndrome Mycosis Fungoid... | 18 Years - | University of Pittsburgh | ||
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | NCT03905135 | Peripheral T-ce... Mycosis Fungoid... Sezary Syndrome Anaplastic Larg... | rhIL-15 rhIL-15 Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | NCT00226993 | Mycosis Fungoid... | CPG 7909 | 18 Years - | Stanford University | |
| Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | NCT00129415 | Atopic Dermatit... Psoriasis Alopecia Mycosis Fungoid... Urticaria Dermatoses Stretch Marks | UVA1 Irradiatio... UVB Irradiation | 10 Years - 80 Years | University of Michigan | |
| Immunization Against Tumor Cells in Sezary Syndrome | NCT00099593 | Cutaneous T-cel... Sezary Syndrome | Autologous Dend... | 18 Years - | FDA Office of Orphan Products Development | |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides | NCT03789864 | Lymphoma, T-Cel... Mycosis Fungoid... | Biodynamic imag... | 18 Years - | Indiana University | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | NCT04955340 | Cutaneous T Cel... Mycosis Fungoid... Sezary Syndrome | [14C]-resminost... | 35 Years - 55 Years | 4SC AG | |
| CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | NCT00185965 | Non-Hodgkin Lym... Mycosis Fungoid... | CPG 7909 | 18 Years - | Stanford University | |
| Forodesine in the Treatment of Cutaneous T-Cell Lymphoma | NCT00501735 | Cutaneous T-cel... | Forodesine 200 ... | 18 Years - | BioCryst Pharmaceuticals | |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | NCT00007345 | Cutaneous T Cel... Peripheral T Ce... | Romidepsin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | NCT00038025 | Peripheral T-ce... Cutaneous T-cel... Chronic Lymphoc... | Deoxycoformycin... | 16 Years - | M.D. Anderson Cancer Center | |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL | NCT02811783 | Mycosis Fungoid... Lymphoma, T-Cel... Sézary Syndrome | Naloxone Hydroc... Placebo Lotion | 21 Years - | Elorac, Inc. | |
| Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | NCT00969085 | Cutaneous T-cel... | Curcumin (Turme... Questionnaires Photos | - | M.D. Anderson Cancer Center | |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | NCT02542124 | Cutaneous T Cel... Mycosis Fungoid... Sézary Syndrome | NM-IL-12 and TS... | 18 Years - | Neumedicines Inc. | |
| Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma | NCT02301494 | Mycosis Fungoid... | 3.75% Imiquimod... 0.1% Fluocinoni... | 18 Years - | Rochester General Hospital | |
| Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | NCT00178841 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Rosiglitazone a... | 18 Years - | Vanderbilt University | |
| Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | NCT03695471 | Mycosis Fungoid... Sezary Syndrome Stage IB Mycosi... Stage II Mycosi... Stage IIA Mycos... Stage IIB Mycos... Stage III Mycos... Stage IIIA Myco... Stage IIIB Myco... Stage IV Mycosi... Stage IVA1 Myco... Stage IVA2 Myco... Stage IVB Mycos... | Pembrolizumab | 18 Years - | Mayo Clinic | |
| An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | NCT00535470 | Mycosis Fungoid... | 0.04% Mechloret... | - | Yaupon Therapeutics | |
| Photopheresis in Early-stage Mycosis Fungoides | NCT05680558 | Cutaneous T Cel... Mycosis Fungoid... | UVADEX® (methox... THERAKOS® CELLE... | 18 Years - | Columbia University | |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light | NCT05872854 | Cutaneous T Cel... Mycosis Fungoid... | Hypericin Visible Light | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma | NCT05538988 | Mycosis Fungoid... | Cemiplimab | 18 Years - | AHS Cancer Control Alberta | |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) | NCT01578499 | Primary Cutaneo... Mycosis Fungoid... Cutaneous T-Cel... | Brentuximab Ved... Methotrexate Bexarotene | 18 Years - | Takeda | |
| The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients | NCT06421571 | Mycosis Fungoid... | 18 Years - | National and Kapodistrian University of Athens | ||
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | NCT00431912 | Cutaneous T-cel... | APO866 | 18 Years - | Valerio Therapeutics | |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | NCT03587844 | Mycosis Fungoid... Lymphomatoid Pa... Sezary Syndrome | brentuximab ved... brentuximab ved... brentuximab ved... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| Cell-free Circulating DNA in Primary Cutaneous Lymphomas | NCT02883517 | Mycosis Fungoid... Lymphoma, Large... | Cytogenetic and... | 18 Years - | University Hospital, Bordeaux | |
| Photopheresis in Early-stage Mycosis Fungoides | NCT05680558 | Cutaneous T Cel... Mycosis Fungoid... | UVADEX® (methox... THERAKOS® CELLE... | 18 Years - | Columbia University | |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | NCT01352520 | CD-30 Positive ... Lymphoma, Prima... Lymphomatoid Pa... Mycosis Fungoid... Skin Lymphoma Cutaneous Lymph... Lymphoma Hematologic Dis... | SGN-35 | 18 Years - | M.D. Anderson Cancer Center | |
| TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | NCT02822586 | Mycosis Fungoid... Sézary Syndrome | TSEB Therapy Brentuximab ved... | 18 Years - | Virginia Commonwealth University | |
| Histopathological Changes in Mycosis Fungoides | NCT05904522 | Mycosis Fungoid... | biopsy | 18 Years - 100 Years | Bezmialem Vakif University | |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | NCT00127881 | Mycosis Fungoid... Sezary Syndrome | HuMax-CD4 (zano... | 18 Years - | Emergent Product Development Seattle LLC | |
| Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | NCT02881749 | Mycosis Fungoid... Cutaneous T-cel... | Total skin elec... mechlorethamine... | 18 Years - | Thomas Jefferson University | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | NCT00535470 | Mycosis Fungoid... | 0.04% Mechloret... | - | Yaupon Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
